Recent Investment Analysts’ Ratings Updates for BridgeBio Pharma (BBIO)

A number of research firms have changed their ratings and price targets for BridgeBio Pharma (NASDAQ: BBIO):

• 1/28/2026 – BridgeBio Pharma is now covered by analysts at Barclays PLC. They set an “overweight” rating on the stock.
• 1/21/2026 – BridgeBio Pharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – BridgeBio Pharma had its price target raised by analysts at Wells Fargo & Company from $84.00 to $88.00. They now have an “overweight” rating on the stock.
• 1/12/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/8/2026 – BridgeBio Pharma had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a “buy” rating on the stock.
• 1/6/2026 – BridgeBio Pharma is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $96.00 price target on the stock.
• 12/15/2025 – BridgeBio Pharma had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – BridgeBio Pharma is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $94.00 price target on the stock.
• 12/11/2025 – BridgeBio Pharma is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $94.00 price target on the stock.

Insiders Place Their Bets

In other news, Director Andrew Lo sold 55,000 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total value of $3,612,950.00. Following the sale, the director directly owned 50,583 shares in the company, valued at $3,322,797.27. The trade was a 52.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Thomas Trimarchi sold 16,934 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $66.46, for a total transaction of $1,125,433.64. Following the transaction, the chief financial officer owned 382,830 shares of the company’s stock, valued at $25,442,881.80. The trade was a 4.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 387,215 shares of company stock worth $26,255,694 in the last three months. 18.20% of the stock is owned by corporate insiders.

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.